সক্ষিত্ৰ কিছিল। শত্ত App আজিলা ha user through 4 কৰে এই স্থালিক কিছিল। কিছিল Butert and Trademark Piller , 5 (PERARUEN) এই আৰু দুৱ এই পিলেগ্ৰা, কম চাইলিকানকু Alt প 1996 শত্ৰেলাগোল লোভাইন জন্মতাৰ জন্মতা চিকালাকুল আৰক্ষি চিকাল মুখ্যালিক

FEE TRANSMITTAL for FY 2003			Complete if Known							
			Apprilation Number				09 451.641			
			Filing Date			November 30, 1999				
Effects e 01 01 2003. Patent fees are subject to annual revision.			First Named Inventor			Gao, D.				
Applicant claims small entity status. See 37 CFR 1.27		Examiner Name				S. Fran		·		
		Group Art Unit			t	1615				
TOTAL AMOUNT OF PAYMENT (\$) \$1,130,00			Attorney Docket No		(-3169 1 1 8					
METHOD OF PAYMENT (check all that apply)			FI	EE CA	LCULATION	ON (continu	ed)			
Check Dredit card Money Other None	3.	ADDITIC	NAL	FEES	3					
Déposit Account	Larg Fee	e Entity . Fee	Smal Fee	L <u>Entit</u> Fee	<u>x</u>					
Deposit Account 19-1025	Cod	e (\$)	Code	(\$)			scription		Fee Paid	
Names 19-1025	105	i	2051			arge - laté filin				
Deposit Second Planne Pharmacia Corporation	108 1-25	!	2052 1,63		sheet	arge - late pro English specif	.,	tee di Livie		
The Commissioner is authorized to Theck at that and is	181					ng a niqui stit		45 (410m to 25) 1		
Durings teek inc. sector will Durestan, Josephynens						sting publicat				
Transfer and a 111 Maris electrical agricultural tensis or this application.					aution					
Charachetisch disafer cerkwie except for the filing fee	180	:5 1,840°	1805	1,8401	Reque action	isting publicati	ión of SIR afte	gf Exten inter		
Latinative dentities despitation	125	1 110	2251	$[\cdot]_{i} \in$	Extens	sion for reply v	vithii: fist mor	itti		
FEE CALCULATION	125	2 410	2252	205	Extens	Sion for reply v	vithin second i	month		
BASIC FILING FEE	125	3 930	2253	465	Extens	sión for reply v	vithin third me	nth	950.00	
Large Entity , Small Entity	125	4 1,450	2254	725	Extens	sion far reply v	athia fourth in	on:h		
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	-25	5 1.970	2255	989	Extens	sion for reply v	athin fifth mor	·in		
1001 #50 2004 375 Utility filing fee	140	1 320	2401	160	Notice	of Appear				
1:02 530 2002 165 Design filing	140	2 320	2402	160	Fing.	a brief in supp	ort of an appe	al		
1 3 620 , 503 260 Plant fing fee	140	3 280	- 7403	140	Reque	est for oral fiea	nng			
1684 750 2004 375 Ressue filing	145					n to institute a	**	sonal ne		
10.5 160 2005 80 Previsional filing fee	145	ė				n foires de cur				
QUBIOTO	145	3 1,300				n to revise Tur				
		1 1 300 1				ssue fee i <i>or</i> re				
2. EXTRA CLAIM FEES FOR UTILITY AND Fee from	150	· · · · · · · · · · · · · · · · · · ·								
Extra Claims below Fee Paid						ssue fee				
Total Claims -20^{**} 0 \times = 0.00	146					ns to the Cons	n ss oner			
Independent Claims 0 X = 0.00	180		1807			sang fee unde		+ 7 ₁₅ ,		
Multiple Dependent	180					ssion of Inform				
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	802	1 40	802*		Statem Record		nt assigilinen		180.00	
1,702 1F 2200 9 Clarms in excess of 20	180	N _m -	2900	375		rannærorgig Esabirissjer a		Lon		
1201 84 2201 42 Independent claims in excess of 3					±37 ČF	R § 1.129(a),).			
1203 280 2203 140 Multiple dependent claim, if not paid	1810	0 750 j	2810	375		ch additional it R - § 1.129(b)		exammed		
1204 34 2204 42 *** Reissue independent claims over original patent	180	750	2801	375		st for Continue		n (RCE)		
12/15 18 2225 9 *** Reissue claims in excess of 20 and over original patent	180			900		st for expedite sign applicatio				
CURTOTALIO	Ot 1	hai foo [S]	Prof _e t			0				
SUBTOTAL (2) (\$) \$0.00										
or number previously paid, if greater, For Reissues, see above	' Re	duced by	Basic	Fring I	Fee Pali	;, SL	BTOTAL (3) (\$) \$1	.130.00	
SUBMITTED BY Complete ** ** april can #**										
Manua Parting			Registration No		39,457 Telephone					
	70. 4 N.		Attorne, Agent		37,45			847-581-60 October 27, 20		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This Collection of information is required by 37 CFR 117 and 1.77. The information is required to obtain or retain a herefit by the public which is to the care this transfer of processes an application. Conflidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 min dies to single by including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary, depending upon the individual case. According to the amount of time you require to complete this form and or suggestions for rectucing this burden, should be sent to the Crief information Office. U.S. Department of Commiscious P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS 10.748. ADDRESS. SEND TO. Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE/ CENTROLS ATTORNEY DOCKET NO.: C-3169 1 E8/6002900

APPLICANT:

SERIAL NO.:

09 451,641

GROUP ART UNIT:

1615

FILED:

November 30, 1999

EXAMINER:

S. Tran

TITLE:

CELECOXIB COMPOSITIONS

DATE:

October 27, 2003

BY HAND DELIVERY TO USPTO FOR THE ATTENTION OF EXAMINER SUSAN TRAN, UNIT #1615

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

PETITION FOR EXTENSION OF TIME

Applicant hereby makes petition for extension of time of three months for response to the Office Action dated May 20, 2003 in the above-referenced application. A shortened statutory period of three months was set. In connection with this petition, please charge \$950.00 or the sum required under 37 C.F.R. § 1.17(a)(3) to Deposit Account No. 19-1025.

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement (IDS) is filed in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and §§ 1.97–1.98, as supplemented by MPEP § 609. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This IDS supplements those submitted on March 24, 2000, October 17, 2001, April 26, 2002, July 10, 2002 and February 18, 2003 and is filed under the provisions of 37 C.F.R. § 1.97(e) accompanied by authorization to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025.

WO 00 15195 was cited (as Japanese Patent Publication No. 2002-5424492A) in an

action by the Japanese patent office. It is noted that neither WO 00 15195 nor its priority document (Danish Patent Application No. 981143) is available as prior art to the present application under 35 U.S.C. § 102(e), as can be established by applying the guidelines of MPEP § 706.02(f)(1).

All documents submitted herewith except WO 00°15195 were cited in oppositions of counterparts of the present application in Israel and at EPO. Of these documents, Basit *et al.* (2001) has a publication date later than the priority date of the present application. To the best of Applicant's belief none of the art cited in the remaining 29 documents is closer to the present invention than art already of record.

The following documents are in a language other than English and Applicant is not in possession of an English language translation of these.

EP 0 256 933 appears to relate to a granular formulation of fenofibrate, an antihyperlipoproteinemic agent, having a fenofibrate particle size not greater than 50 μm .

EP 0 330 532 is believed to be a counterpart of US 4,895,726, also presented herein, and appears to relate to a gelatin capsule formulation containing co-micronized fenofibrate and solid surfactant, having a mean particle size of the co-micronized mixture of less than 15 μ m.

Bauer *et al.* (1991) appears to disclose, on page 104, a table of particle sizes and, on page 203, a general discussion of micronization of drugs.

List (1985) appears to provide a general discussion of dissolution rate.

Voigt (1984) appears to provide a general discussion of drug dissolution.

Applicant regrets that some of the documents provided herewith are poor-quality copies, but they are the best copies presently available to Applicant, and all are legible.

COMMENTS ON INTERVIEW ON OCTOBER 23, 2003

Applicant appreciates the courtesy shown to the undersigned by Examiner Tran and Supervisory Examiner Page in a personal interview in the present matter on October 23, 2003. Applicant agrees that the Interview Summary prepared by the Examiner is an accurate record of the substance of the interview, but adds that it was agreed that rejoinder of method of use claims (Claims 72–75) would be accepted by the Examiner. It was further agreed that Claims 84-90, being composition claims dependent from Claim 1, should be considered together with Claims 1–50 instead of with the process claims (Claims 76–83 and 91-94) as in the Office Action dated

May 20, 2003.

By amendment as proposed herein, the claims are put in condition for immediate allowance as agreed during the interview, subject to the Examiner's review of the art cited in the IDS submitted herewith. The Examiner agreed to call the undersigned upon receipt and consideration of the present amendment and response.

In compliance with the format for amendments now required, an amendment follows, beginning on a separate page.